In a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, talks about Infosys' latest numbers. Excerpts: ET Now: Prima facie, Infosys' numbers look okay. What is your take? Sarabjit Kour Nangra: Infosys' topline has positively surprised. 4.5% ... Economic Times, 1 week ago
See no dramatic impact of H1-B probe on TCS, Infosys: Angel - Moneycontrol.com, 1 month ago
1 images for "sarabjit kour nangra"
Tech Mahindra and many small caps have indicated trend of lower revenue for Q1: Sarabjit Kour Nangra
In an interview with ET Now, Sarabjit Kour Nangra from Angel Broking expresses her outlook on lower revenue trends indicated by Tech Mahindra and other IT organizations. ET Now: Tech Mahindra has come out with its report, they are saying that the ...Economic Times, 1 month ago
Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel Broking
I believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance for the current year. In an interview with ET Now, Sarabjit Kour Nangra, VP - Research, Angel Broking, Pharma, shares his ...Economic Times, 1 month ago Ranbaxy effect playing on Sun Pharma's margins: Pros Money Control, 2 months ago
With global clients reviewing their investments in traditional technology upgradation and, instead, investing in newer technologies like cloud, analytics and social media, competition among information technology (IT) outsourcing services providers ...Smart Investor, 1 day ago IT firms face pricing pressure as clients review spending Smart Investor, 1 day ago
Chennai IT major Tech Mahindra reported a net profit of Rs 676.07 crore for the quarter ended June 30, 2015, compared to Rs 630.72 for the corresponding quarter the previous year. However, the company’s operating profit was down from Rs 779.20 crore in Q1 ...The Financial Chronicle, 2 days ago Tech Mahindra shows profit of Rs 676 cr in first quarter Financial Chronicle, 2 days ago Wipro Q1 net profit up 4% at Rs2,187 cr The Financial Chronicle, 6 days ago Tech Mahindra Q4 PAT at Rs 472 crore The Financial Chronicle, 2 months ago
Software solutions provider Tech Mahindra surpassed street expectations on bottomline & operational front Monday while revenue met estimates. Consolidated net profit in first quarter climbed 43 percent sequentially to Rs 676 crore, supported by ...Moneycontrol.com, 2 days ago Tech Mahindra gains 2% on tie up with BPM software vendor Moneycontrol.com, 3 weeks ago TechM projects tepid Q1 revenues, stock dives 7% The Financial Chronicle, 1 month ago
Indian pharmaceutical companies and industry experts do not see a downside for Indian drug makers following drug maker Teva's $40 billion dollar acquisition of Allergan.Jerusalem-based Teva was the world's largest generic drug maker by sales in ...Smart Investor, 2 days ago
The European Commission, the executive body of the European Union (EU), has formally put into effect the suspension of 700-odd drugs that underwent bio-equivalence studies at a facility of Hyderabad-based GVK Bio Sciences. The suspension had been ...Business Standard India, 3 days ago EU-wide ban on suspended drugs from August 21 Smart Investor, 4 days ago
India's pharma sector has been presenting mixed growth trends. On the one hand, growing demand is presenting an opportunity, while on the other, many factors are impacting the non-homogeneous sector. Some recent key developments included fixing of price caps ...The Financial Chronicle, 3 days ago
Acquisition of US-based co for $880 million is biggest by an Indian drug maker; gives Lupin 66 abbreviated new drug application filings over 65 products under development In biggest acquisition by an Indian drugmaker overseas, Lupin on Thursday ...DNA India, 6 days ago Lupin gets first US plant with GAVIS buy [DNA : Daily News & Analysis (India)] Pharmacy Choice, 4 days ago Lupin gets US FDA approval for anti-diabetes drug Business Standard India, 1 week ago
on your WebpageAdd Widget >Get your members hooked!